🔗 Permalink

Inventor profile of:

Mark Cornell Manning

City:

Johnstown, Colorado

Country:

United States

Published Applications:

Last publication date:

2025-04-10

Top Assignees for applications by Mark Cornell Manning

The entities that hold a legal rights for patent applications filed by inventor Manning Mark Cornell:

Shire ViroPharma Incorporated 5 Lexington, MA United States
KINIKSA PHARMACEUTICALS, LTD. 3 Hamilton, Bermuda
ViroPharma Biologics LLC 2 Lexington, MA United States
Airway Therapeutics, Inc. 2 Marietta, GA United States
H. LUNDBECK A/S 1 Valby, Denmark
TRACON PHARMACEUTICALS, INC. 1 SAN DIEGO, CA United States

Recent patent applications by Manning Mark Cornell

Mark Cornell Manning from Johnstown, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-04-10

US20250114449A1

Human necessities

STABLE ANTI-OSMR ANTIBODY FORMULATION

#2 | 2025-03-13

US20250084156A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES

#3 | 2024-12-26

US20240425567A1

Chemistry; metallurgy

PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF

#4 | 2024-01-25

US20240025979A1

Chemistry; metallurgy

Compositions and methods for treating synucleinopathies

#5 | 2022-03-03

US20220062414A1

Human necessities

Stable Anti-OSMR Antibody Formulation

#6 | 2021-04-29

US20210121536A1

Human necessities

METHODS AND COMPOSITIONS COMPRISING SURFACTANT PROTEIN D (SP-D)

#7 | 2021-01-14

US20210010988A1

Physics

SYSTEMS AND METHODS FOR CHARACTERIZING SURFACTANT PROTEIN D (SP-D) OLIGOMERS

#8 | 2020-08-20

US20200261556A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#9 | 2020-02-27

US20200061188A1

Human necessities

Stable anti-OSMR antibody formulation

#10 | 2019-05-30

US20190160158A1

Human necessities

C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY

#11 | 2019-05-30

US20190160157A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#12 | 2019-02-21

US20190054169A1

Human necessities

Stable anti-OSMR antibody formulation

#13 | 2018-11-22

US20180333489A1

Human necessities

Stable anti-OSMR antibody formulation

#14 | 2018-11-01

US20180311359A1

Human necessities

Antibody Formulations and Uses Thereof

#15 | 2018-06-07

US20180153972A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#16 | 2018-04-26

US20180110844A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#17 | 2018-04-26

US20180110843A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#18 | 2018-03-29

US20180085441A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#19 | 2017-08-10

US20170224788A1

Human necessities

C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY

#20 | 2016-01-21

US20160015795A1

Human necessities

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

#21 | 2015-07-30

US20150209430A1

Human necessities

Antibody formulations and uses thereof

InventorID:

1238009 ⎘